25 / PRNewswire / -- ChemoCentryx , Inc . , announced today that Phase II / III clinical data from the Company 's PROTECT-1 ( the Prospective Randomized Oral Therapy Evaluation in Crohn 's disease Trial ) of Traficet-EN ( TM ) ( CCX282-B ) in patients with moderate-to-severe Crohn 's disease demonstrated clinical efficacy with a favorable safety and tolerability profile . The study demonstrated evidence of clinical efficacy in the reduction of disease severity as defined as a 70-point decrease in the Crohn 's Disease Activity Index ( CDAI ) in patients treated with Traficet-EN over the course of 12 weeks ; the more stringent measure of at least a 100-point decrease in the CDAI score was also met by week 12 . In addition , Traficet-EN treatment benefited patients who had previously not responded to anti-TNF treatment . These results reported from the Induction phase of the PROTECT-1 trial , were presented today in a poster titled " PROTECT-1 Study of Intestine-Specific Chemokine Receptor Antagonist CCX282-B ( TRAFICET-EN ) in Crohn 's Disease " by Satish Keshav , M.D. , Department of Gastroenterology , John Radcliffe Hospital , Oxford University at the GASTRO 2009 United European Gastroenterology Federation and World Gastroenterology Organization ( UEGW / WCOG ) conference in London .